Please assess the completion status of the following clinical trial:

Trial Title: Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Positive ANA result at visit 1~* Current diagnosis of systemic lupus erythematosus (SLE) by American College of Rheumatology revised criteria such that at least 4 of the 11 criteria are met~* Active moderate or severe SLE disease activity as demonstrated by British Isles Lupus Assessment Group (BILAG) A level disease activity in at least one body/organ system or BILAG B level disease activity in at least two body/organ systems if no BILAG A level disease is present~* If on antimalarials, dose regimen must be stable for 4 weeks prior to study entry.~Exclusion Criteria:~* Patients receiving any live vaccination within 2 weeks prior to visit 1 or during the course of the study~* Active severe SLE disease activity which involves the central nervous system (CNS) (defined by BILAG neurologic A level activity) including transverse myelitis, psychosis and seizures~* Active severe SLE disease activity which involves the Renal system (defined by BILAG renal level A activity or Grade III or higher World Health Organization (WHO) nephritis) or serum creatinine \>2.5mg/dL or clinically significant serum creatinine increase within the prior 4 weeks or proteinuria \>3.5gm/day~* Patients with a history of anti-phospholipid antibody syndrome AND use of oral anticoagulants or anti-platelet treatment~* Patients with a history of chronic infection, recent significant infection, or any current sign of symptom that may indicate an infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Phosphate-buffered Saline (PBS) infusions at study weeks 0, 1, 2, and 3.
- EMAB 600mg (Type: EXPERIMENTAL): 600 mg Epratuzumab infusions at study weeks 0, 1, 2, and 3.
- EMAB 100mg (Type: EXPERIMENTAL): 100 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
- EMAB 400mg (Type: EXPERIMENTAL): 400 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
- EMAB 1200mg (Type: EXPERIMENTAL): 1200 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
- EMAB 1800mg (Type: EXPERIMENTAL): 1800 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).